ABOUT 22nd_BEF
> ATTENDEES​​
> INVESTORS​​
> PRESENTERS
> EXHIBITORS​
​> SPONSORS​​​
> SUPPORTERS​​

In-person presenters:

20-minute Presenters

Addex Therapeutics Ltd.

Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available, small molecule drugs known as allosteric modulators for neurological disorders.​

www.addextherapeutics.com/en/

Adrenomed AG

Adrenomed is a privately owned late-stage development biotech company dedicated to restoring Adrenomedullin mediated vascular integrity in critically ill patients with limited treatment options.

The Company’s lead product candidate is Adrecizumab, a first-in-class non-blocking biological that targets a previously unaddressed pathophysiological mechanism in sepsis with personalized care by targeting Adrenomedullin (ADM) coupled with bio-ADM as a biomarker for patient identification.

Our current lead indications are sepsis and septic shock and with Adrecizumab we are addressing a significant high unmet medical need.

www.adrenomed.com/

Anaveon AG

We are exploiting the power of cytokines to orchestrate immune responses by using protein engineering to create safe and effective treatments for a variety of serious diseases.

The first drug we have taken into clinical trials is a selective interleukin-2 (IL-2) receptor agonist which is a fusion protein of a highly specific anti-IL-2 antibody and IL-2: ANV419. We have shown that our lead compound ANV419, can selectively promote the function of immune effector cells, making it a potential treatment for a range of cancer types. Taking ANV419 into clinical testing has now brought it a step closer to the patients who need it.

Beyond ANV419, we have a pipeline that features targeted cytokines under development to treat a range of diseases. In the future, our work may involve securing additional funding and forging partnerships to strengthen our programs.

We will continue to harness the power of cytokines, leveraging the expertise of our team and our state-of-the-art facilities to develop treatments that benefit society.​

anaveon.com/

BioInvent International AB
[NASDAQ:BINV]

BioInvent International AB is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The Company’s validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company’s own clinical development pipeline or for additional licensing and partnering.

The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company’s fully integrated manufacturing unit.

www.bioinvent.com

BioVersys AG

BioVersys AG is a privately-owned clinical stage Swiss pharmaceutical company focusing on research and development of small molecules acting on novel bacterial targets with applications in Antimicrobial Resistance (AMR) and targeted microbiome modulation.

With the company’s award-winning TRIC technology we can overcome resistance mechanisms, block virulence production and directly affect the pathogenesis of harmful bacteria, towards the identification of new treatment options in the antimicrobial and microbiome fields. By this means BioVersys addresses the high unmet medical need for new treatments against life threatening resistant bacterial infections and bacteria-exacerbated chronic inflammatory microbiome disorders.

*) Last private investment round: CHF 24 million already raised in a first Closing, 2nd Closing has CHF 10 million open – target Q4 2022.

*) Pipeline of 4 distinctly different projects (different modes of action)
+ 2 clinical stage Phase II ready programs directed at severe hospital acquired pneumonia and tuberculosis
+ 2 fast followers in preclinical development
+ Significant external validation via big pharma collaboration (GSK) and exceptionally high success in non-dilutive funding (up to CHF 30 mio)

*) Experienced team
*) Qualifies as impact investment touching important UN ESG goals for global health

Our most advanced R&D programs address nosocomial infections of Acinetobacter baumannii (BV100, Phase 2 ready), and Tuberculosis (BVL-GSK098, Phase 2 ready) in collaboration with GlaxoSmithKline (GSK) and a consortium of the University of Lille.

BioVersys is located in the Technologiepark in the thriving bio-tech hub of Basel.

www.bioversys.com/

Epsilogen Ltd

Epsilogen is a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer. IgE has several key features that make it ideal for the treatment of solid tumours including greater potency, enhanced tumour access and a long tissue half-life.

The company’s lead product candidate, MOv18 IgE, is in a phase I clinical trial in folate receptor alpha positive cancer patients. This is the world’s first IgE drug to enter clinical trials. Epsilogen has constructed a novel and proprietary pipeline of anti-cancer IgE antibodies.

www.epsilogen.com/

GBC-HpVac SA

HpVac is a late-stage preclinical company developing a first in class, disease modifying drug to transform the health of allergic patients.

HpVac's science is based upon a discovery that a member of the human gastrointestinal microbiome actively modulates the human immune system and protects against allergic diseases.

The company has developped and optimized a proprietary compound derived from the unique protein responsible for this protection. It has generated robust data both in vitro and in animal models, in preventive and acute settings.

The project is also underpinned by epidemiological studies, and positive past experiences in humans with respect to the safety profile of the molecule.

HpVac is now about to start the pre-IND filing phase.

www.hpvac.ch/

GeNeuro SA
[EPA: GNRO]

GeNeuro is a Swiss-based clinical stage company committed to bringing safe and effective solutions for stopping the progression of neurodegenerative diseases, such as Multiple Sclerosis (MS), Post-COVID (PASC) and Amyotrophic Lateral Sclerosis (ALS).

www.geneuro.com

Glycostem Therapeutics B.V.

Glycostem Therapeutics is focused on the development of stem cell-derived Natural Killer cells (NK cells) as a medicinal asset in the fight against cancer. NK cells are the new star in the domain of cellular immunotherapy, due to their tightly regulated “natural killing” of cancer cells; they play an important role in control and even cure of both solid and hematological malignancies, like Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM).

Our mission is to focus on the research, development, production and medical use of NK cells based therapies and work with selected partners looking after patients, staff and the environment.

Our vision is to be the leading innovative NK cell therapy company covering strong unmet medical needs.

Over the last decade we studied the role of NK cells in cancer treatment extensively and pioneered, developed and optimized our in-house NK cell production processes. A growing number of commercial and academic partners have chosen Glycostem because of our expertise with NK cells and their production.
​
During our phase I safety study we verified our lead product oNKord® (unmodified NK cells) to be a safe therapeutic agent in the field of cellular immunotherapy. Currently we are developing our second product: Chimeric Antigen Receptor (CAR)-engineered NK cells. This second-generation product has dedicated functionality, enhances tumor targeting and prolongs persistence.

www.glycostem.com

InterK Peptide Therapeutics Ltd

InterK Peptide Therapeutics Limited is a preclinical biotechnology company that has developed small, non-naturally occurring peptides which modulate the immune system.

InterK functions largely as a virtual company located in Sydney, Australia, and the company owns all intellectual property associated with its research and technologies.

InterK's peptides may have therapeutic benefit against autoimmune diseases, eg, as complementary treatment together with cancer immunotherapy, as an adjuvant in anti-viral/anti-cancer vaccination strategies and in the repair of ultraviolet radiation-induced skin damage.

www.interk.com.au/

Macomics Ltd.

Macomics is developing precision medicines to modulate macrophages for the treatment of cancer. Our vision is to develop new approaches to target the immunosuppressive tumour microenvironment, that exploits disease specific macrophage biology to harness the power of the immune system.

We have a portfolio of antibody programs progressing towards clinic and continue to identify new therapeutic targets through it's proprietary target identification approach. By combining analysis of human disease tissue, in silico data mining, and functional data from state-of-the-art cellular models we continue to identify and validate new drug targets in diseases where macrophages play a central role.

The company was co-founded in 2020 by Prof Jeffrey Pollard and Dr Luca Cassetta, University of Edinburgh, internationally recognised leaders in macrophage biology.

www.macomics.com/

Marker Therapeutics, Inc.
[NASDAQ: MRKR]

Marker Therapeutics (Marker) is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Marker developed lead product candidates from MultiTAA-specific T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. ​

www.markertherapeutics.com/

mendus ab
[STO: IMMU]

Mendus AB (publ) is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. Upcoming milestones 2022H2: survival data Phase II trial in AML maintenance, initial data Phase I trial in ovarian cancer, multiple preclinical milestones.

www.mendus.com/

NH TherAguix SAS

NHTherAguix (France) is a Phase II biotechnology company developing AGuIX® radiosensitizing nanoparticles that increase the effectiveness of radiotherapy . Designed to increase the dose differential between tumours and healthy tissues, AGuIX® also allows more accurate radiotherapy imaging guidance.

AGuIX® has first been extensively tested in various preclinical models (>70 scientific papers, 14 patent families).

So far, AGuIX® has been injected in > 90 patients. Results of the FIH Phase I trial in brain metastasis (NANORAD1, 15 pts/15, France) have confirmed the triple effect (targeting, imaging, treating) and doses safety profile (Verry Science Advances 20, Verry Radiotherapy & Oncology 21).

AGuIX® is undergoing 2 Phase II randomized trials in brain metastasis using either panencephalic radiotherapy, (NANORAD2, 73 pts/100, 12 centers, France) or stereo-radiosurgery, (NANOBRAINMETS, 25 pts/134, Dana Farber Cancer Institute, Harvard). NANORAD2 preliminary results (58 patients analyzed) show an iPFS/OS signal promising when compared to the control arm (disclosable under NDA).

In parallel, 3 other exploratory Phase Ib-II trials are underway with significant newsflow for Q4-23/Q1-24 :
• pancreatic and lung cancers (NANOSMART, 15 pats/100, DFCI, Harvard)
• glioblastoma (NANOGBM, 2 pt/66, multicentric, France)
• advanced cervix cancer (NANOCOL, 12 pts/12, IGR)

NH TherAguix is looking for a ~€40M B series to (ii) consolidate evidence of clinical activity already seen on brain metastasis (iii) prepare/start clinical trials in sponsored selected indications in Orphan Drug Disease with important unmet needs, identified regulatory pathway, readout short as possible, minimized risk .

NHTherAguix was founded in 2015, Géraldine Le Duc (CEO of NH TherAguix since inception) and Olivier Tillement (Professor of chemistry at University of Lyon). NHTherAguix raised €29M (dilutive/non-dilutive) including a €13M A series in 2019. The management team is composed of Hervé Brailly (Innate Pharma) as chairman, Olivier de Beaumont Chief Medical Officer, and Géraldine Le Duc as CEO.

http://nhtheraguix.com/

Oryzon Genomics, S.A.
[BME: ORY]

A public clinical-stage biopharma developing epigenetics for CNS disorders and Oncology. +50 highly-qualified professionals located in Barcelona, Boston, NYC and San Diego. Listed in Spain, aiming at NASDAQ-listing.
​
Two uncorrelated Phase II compounds: iadademstat (oncology) and vafidemstat (CNS).
Iadademstat, best-in-class LSD1 inhibitor, is in clinical development for AML and solid tumors. PoC with strong clinical activity in combo with azacitidine in a Phase II in unfit AML patients, and encouraging signals in 2L-ED-SCLC. Currently launching new trials in AML, SCLC and neuroendocrine tumors.

Pioneering development of epigenetic drugs in CNS with vafidemstat, a safe LSD1 inhibitor. Positive results reducing aggression in a Phase IIa basket trial in psychiatric patients. Two Phase IIb trials in borderline personality disorder and schizophrenia actively recruiting. Also launching a CNS personalized medicine program, starting with a Phase I/II trial in Kabuki syndrome.

www.oryzon.com/en

PharmAbcine Inc.
[​KOSDAQ: 208340]

PharmAbcine is a clinical stage public company developing next generation IgG based therapeutics to treat cancer, neovascular eye diseases, and vascular related unmet needs.

After the Olinvacimab + Keytruda combo in mTNBC delivered 50% ORR, 67% DCR and clean safety, Phase II study is ongoing. In contrast to bevacizumab, cyramza, lenvatinib or axitinib, olinvacimab does not cause hypertension, GI perforation, internal bleeding/hemorrhage, and proteinuria, suggesting ideal properties for combination therapeutics.

We have three novel IND ready assets with a first-in-class potential:
1) PMC-309, an anti-VISTA-antagonizing IgG, is an immune check-point regulator that targets MDSC (myeloid derived suppressor cells) and M2 macrophages which play pivotal role in maintaining immunosuppressive TME (Tumor Microenvironment). All comers with advanced cancer will be recruited for Phase I trial.
2) PMC-403 is a TIE2-activating antibody that stabilizes dysfunctional leaky disorganized pathological vessels. Wet AMD patients who are suboptimal responding to Lucentis and Eylea will be recruited for Phase I trial.
3) PMC-402 is a TIE2-activating antibody that stabilizes dysfunctional leaky disorganized pathological vessels. Diabetic patients with Diabetic Peripheral Neuropathy will be recruited for Phase I trial.

Our non-clinical stage asset, PMC-005, is an anti-EGFRviii IgG that only binds to EGFRviii expressed on cancer cells and shows no binding to EGFR wild type. It can be applied to various modalities including CAR-T, CAR-NK, CAR-Macrophage, T cell engager, NK cell engager and Radio-Immunotherapy. Various collaborators showed their CAR-T using PMC-005 eradicated EGFRviii-positive tumor in animal model systems.

We are looking for strategic investors, codevelopment partners, opportunities for licensing-out, option deal or JV.

www.pharmabcine.com

QurAlis

At QurAlis, we are pioneering the path to conquering ALS and other neurodegenerative diseases with genetically validated targets with next-generation precision medicines. Our proprietary platforms and unique biomarkers enable the design and development of precision medicines that act directly on disease-causing genetic alterations.

We are advancing a deep pipeline of antisense oligonucleotides (ASOs) and small molecule programs addressing sub-forms of ALS that account for the majority of ALS patients. And, we are leveraging our insights, platforms, and successes in ALS to collaborate and expand our pipeline to other neurodegenerative diseases, such as frontotemporal-degeneration (FTD).

Our goal is to halt disease progression and significantly improve outcomes.

Our mission is to make a meaningful difference in patients’ lives.

That is QurAlis.

www.quralis.com

​Rejuveron Life Sciences AG

Rejuveron is a clinical-stage biotechnology company creating therapies to improve healthy aging. Its experienced drug discovery and development team applies a deep understanding of the biology of aging, alongside technological advances in biopharmaceutical R&D, to progress a new generation of medicines that will help people to age better and live longer.

​rejuveron.com

Relief Therapeutics Holding SA
[SIXL RLF.SW  / OTCQB: RLFTF / OTCQB: RLFTY]

Relief is a Swiss, commercial-stage, biopharmaceutical company focused on identification, development and commercialization of novel, patent protected products intended for the treatment of metabolic, dermatological and pulmonary rare diseases with a portfolio of clinical and marketed assets that serve unmet patient needs. Relief has a Collaboration and License Agreement with Acer Therapeutics for the worldwide development and commercialization of ACER-001 (sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including UCDs and Maple Syrup Urine Disease (MSUD). Relief also continues to develop aviptadil for several rare pulmonary indications. Relief's 2021 acquisitions of APR Applied Pharma Research SA and AdVita Lifescience GmbH brought to Relief a diverse pipeline of marketed and development-stage programs.
​
www.relieftherapeutics.com/

Revolo Biotherapeutics

We are a revolutionary biotherapeutics company and our mission is to revolutionize autoimmune and allergic disease treatment by resetting the immune system for superior long-term disease remission. By developing therapies that achieve superior long-term disease remission from less frequent chronic dosing and without suppression of the immune system. A goal that others haven’t been able to reach. Existing therapies for autoimmune and allergic diseases require frequent chronic dosing, provide only short-term disease remission in a limited number of patients and suppress the immune system, ultimately putting patients at risk of developing serious infections and life-threatening side effects.

Our two platform drug candidates, ‘1805 and ‘1104, reset the immune system after only a single administration in an unmatched way. They have demonstrated unique efficacy and safety in preclinical and human studies – without immune suppression. Given our disease-agnostic approach, we are uniquely positioned as revolutionaries in the development of drugs for various autoimmune and allergic diseases.

www.revolobio.com/

STALICLA SA

Stalicla SA is a Swiss clinical stage biopharmaceutical company leading omics-based precision medicine drug development for patients with neurodevelopmental disorders (NDDs), with a first application in autism spectrum disorder (ASD). Stalicla is on a unique mission to identify clinically actionable patient subgroups and develop tailored treatments for those most impaired by their symptoms. Its DEPI technology is the first platform specifically developed to enable precision medicine in complex NDDs. The platform integrates comprehensive metabolomics, whole-genome sequencing, RNA sequencing and its advanced HC match module to pair patient biological signatures with drug candidates. DEPI has reached clinical proof of concept with its lead pipeline candidate, STP1, addressing a first biological subgroup of patients with ASD. In 2023, STP1 will enter Phase 2 following a recent successful phase 1b; STP2 (SFX-01), STALICLA’s additional pipeline addressing a second biological subgroup of patients will also be entering Phase 2.Stalicla is advancing collaborative alliances with strategic third-party pipelines and is rapidly scaling its platform and clinical development activity.

www.stalicla.com

TME Pharma
[EPA: ALTME]

TME Pharma is a clinical-stage company focused on developing novel therapies for treatment of the most aggressive cancers. TME Pharma’s pipeline acts by neutralizing chemokines in the TME. TME Pharma’s approach works in combination with other forms of treatment to overcome resistance to immunotherapies such as CPIs, CD3 bi-specifics, anti-vascular agents and cell therapies to increase therapeutic impact.

http://www.tmepharma.com/

Ultimovacs ASA
[Euronext Oslo: ULTI.OL]

Ultimovacs is an immunotherapy company developing immune-stimulatory vaccines to treat a broad range of cancers. Ultimovacs’ lead universal cancer vaccine candidate UV1 targets human telomerase (hTERT), present in 85-90% of cancers in all stages of tumor growth. By directing the immune system to hTERT antigens, UV1 drives CD4 helper T cells to the tumor to activate an immune system cascade and increase anti-tumor responses. With a broad Phase II program in five cancer indications enrolling more than 650 patients, Ultimovacs aims to clinically demonstrate UV1’s impact in multiple cancer types, in combination with other immunotherapies, for patients with unmet needs. Ultimovacs’ second technology approach, based on the proprietary Tetanus-Epitope-Targeting (TET) platform, combines tumor-specific peptides and adjuvant in the same molecule and entered Phase I studies in 2021.​

www.ultimovacs.com/

10-minute Presenters

Acthera Therapeutics Ltd.

Acthera Therapeutics is a Swiss early-stage biotech developing mechano-responsive hard-shelled liposomes (HSL) for the targeted and controlled delivery of therapeutic agents. Our unique and innovative technology allows the release of drugs where and when they are needed, with an improved efficacy and safety, for an enhanced efficiency.​

www.acthera-therapeutics.com/

Adiposs SA

Adiposs SA is a Swiss privately-owned clinical-stage biotechnology company developing medical imaging drugs.

The Company's flagship asset is ImageBAT™, a first-in-class contrast agent for non-invasive detection of brown fat. ImageBAT™-enhanced CT scan is simple, fast and scalable worldwide. It can identify cancer patients likely to respond to cancer immunotherapy treatments, the new standard-of-care in oncology. ​
​
​adiposs.com/

Apaxen S.A.

Apaxen develops First-in-Class small molecule NLRP3 inflammasome inhibitors for treatment of inflammatory and auto-immune diseases. Lead compound MFC-1040 is expected to enter start clinical testing by early 2023.​

www.apaxen.com/

Atamyo Therapeutics SAS

Atamyo Therapeutics is a clinical-stage biopharma focused on the development of a new generation of effective and safe gene therapies for neuromuscular diseases.

A spin-off of gene therapy pioneer Genethon, Atamyo leverages unique expertise in AAV-based gene therapy and muscular dystrophies from the Progressive Muscular Dystrophies Laboratory at Genethon. Atamyo’s most advanced programs address different forms of limb-girdle muscular dystrophies (LGMD).
​
Atamyo's seasoned management has a unique Research and Development expertise in the field of Gene Therapy.

ATA-100, a single-administration gene therapy candidate for LGMD2I/R9 is in phase 1b clinical trial in Europe. LGMD2I/R9 is a rare genetic disease caused by mutations in the gene that produces fukutin-related protein (FKRP) and affects an estimated 5,000 people in the US and Europe.

The name of the company is derived from two words: Celtic Atao which means “Always” or “Forever” and Myo which is the Greek root for muscle. Atamyo conveys the spirit of its commitment to improve the life of patients affected by neuromuscular diseases with life-long efficient treatments.

www.atamyo.com

Atriva Therapeutics GmbH

ATRIVA - Beyond antivirals: Providing medicines for a world free of pandemic threats

Atriva, founded in 2015, pursues an approach encompassing first-in-class host-targeting therapies to treat respiratory viral infections, including COVID-19, influenza, hanta virus, RSV and dengue fever amongst others. The company is in Phase II clinical development with first results demonstrating the value of the medical treatment approach of Zapnometinib. The compound has great potential against a wide variety of respiratory viruses due to the immunomodulating and antiviral activity of ATRIVA’s lead product zapnometinib (INN). The company has a highly experienced management team with a comprenhensive track record in general management, fundraising & partnering, CMC, clinical and preclinical development. It is supported by a strong advisory and scientific board of known industry leaders.
​
www.atriva-therapeutics.com

Biomunex Pharmaceuticals

Biomunex is a biopharmaceutical company focused on providing differentiated immuno-therapeutics through the discovery and development of bi- and multi-specific antibodies, created from its proprietary BiXAb® platform. Biomunex has recently announced the unique and disruptive MAIT cell engagers approach for lead immuno-oncology program.

www.biomunex.com/

CeiROx Life Sciences SA

CeiROx Life Sciences (“CeiROx”) is a Swiss life sciences company focused on the development and commercialization of novel, minimally-invasive regenerative medicines for the joints.

Its lead product is Chondrotissue®, - a commercial-stage, proprietary and unique solution with long-term efficacy data in knee joint cartilage regeneration in >6,500 patients treated in Europe and the Middle-East -, entering pivotal studies in the US under an FDA Breakthrough Product Designation obtained in September 2021.

CeiROx is aiming at addressing a $1.8 billion US market in knee joint regeneration alone, with a clear path to enlarged indications into other synovial joints (hip, ankle and MTP1) and several follow-on novel products.

It is led by a longstanding collaboration between Swiss regenerative medicines specialists and technology from world leading German academic centers.

ceirox.com/

Domain Therapeutics SA

Domain Therapeutics, a biopharmaceutical company operating in France and Canada, is dedicated to the discovery and development of new drug candidates targeting G Protein-Coupled Receptors (GPCRs), one of the most important classes of drug targets. The company focuses on developing high-value drug candidates to tackle GPCR-mediated immunosuppression.

Domain raised €39M series A in May 2022.

www.domaintherapeutics.com

Enbiosis BIOTECHNOLOGY

The future of health is hidden in your microbiome and we at ENBIOSIS guide you to find what is hidden in your guts.

Producing scientific inventions, products, and services by using microbiome organisms, we aim to improve the quality of human health. With our artificial intelligence-powered technologies, we analyze the human gut microbiome to provide personalized health solutions that cover a unique microbiome diet program and prebiotics.​

www.enbiosis.com/

Ermium Therapeutics

Ermium Therapeutics, a French biotech in the auto-immune disease space, is based on the recently published breakthrough finding at CNRS and University of Paris Cité, showing that the well-known G protein-coupled receptor (GPCR) chemokine receptor, CXCR4, acts in controlling the release of type I interferons (IFN) by immune cells.

Derived from this novel mechanism of action, and in contrast to classical CXCR4 antagonists, Ermium compounds allow to control efficiently the production of type 1 IFN by plasmacytoid dendritic cells (pDC) known to play a central and upstream role in the inflammatory cascade.

First chemical series generation, and proof of concept in several animal models of auto-immune diseases have opened the door to the discovery of a brand-new class of drugs to be developed by Ermium.

In terms of clinical indications, Ermium compounds will address auto-immune diseases and more particularly type I IFN-driven diseases that include systemic lupus erythematosus (and also Sjogren’s syndrome, dermatomyositis, pemphigus, and monogenic interferonopathies). In this disease, with a high unmet medical need, type I IFN is a clinically validated target.

In this context Ermium compounds exhibit the following advantages:
> ability to potently downmodulate type I interferons and other key inflammatory cytokines;
> modulation of a panel of key immune cells, including pDC;
> oral administration, a key property for drug candidates aimed to be used in chronic diseases.

A drug candidate (DC) will be selected by March 2023 and company will then enter into non clinical development.
Ermium Therapeutics has already raised €12.3 M of dilutive funding with Kurma Partners, Fountain Healthcare Partners, Eurazeo, and Domain Therapeutics as reference investors. Ermium will achieved a capital increase of 30 – 35 M€ after the DC selection.

www.ermium.com

Fab’entech

Founded in 2009, FABENTECH is a French biotech company specialized in the development and production of polyclonal antibodies intended for treating emerging infectious diseases, and for biodefense solutions.

In a context of proliferating risks linked to epidemics and biological threats, FABENTECH is a key player for taking up the major contemporary public health challenges. The company has 12 years of experience developing treatments for human use against deadly emerging diseases and biotoxins such as Crimean-Congo Haemorrhagic Fever, Ebola, H5N1, biotoxins and Covid-19.

A player that already has its own high-performance proprietary industrial tool making it possible to produce its therapeutic solutions quickly and on a large scale.

FABENTECH’s know-how is based on a safe, tried and tested polyclonal antibody technology, initially developed by Sanofi Pasteur and enhanced over more than ten years by FABENTECH’s R&D and industrial teams.

The antibodies are produced by Fabentech for patient unable to produce naturally. They have the capacity to recognize and neutralize the virus or toxin in just a few minutes, and stop the development of the disease or poisoning.​

fabentech.fr

Hoba Therapeutics ApS

Hoba Therapeutics is developing innovative treatments for multiple indications within chronic pain disorders and hearing loss; indications with a large, worldwide unmet medical need for safe and efficacious treatments.

We are seeking investors for our Series A seeking up to EUR 40 M. More than half is already secured by our current investors, and with the participation of the European Innovation Council Fund.

www.hobatherapeutics.com/

Iama Therapeutics S.r.l.

At IAMA Therapeutics, a series-A pharmaceutical company, we are constantly pushing the boundaries of neuroscience drug discovery to develop new medicines and make a difference in the lives of individuals suffering from brain disorders and their families. Our purpose is to provide a therapeutic solution to children and adults suffering from neurological conditions and provide their families with the support they need.

We have developed a platform to identify and advance diverse classes of small molecules to selectively target cation chloride cotransporters (CCCs) and other therapeutic targets relevant to treating central nervous system disorders.

www.iamatherapeutics.com/

IGYXOS SA

Igyxos, a French biotechnology company is developing IGX12, a First-In-Class treatment for female and male infertility; based on an innovative proprietary technology dedicated to human reproductive health. IGX12 holds promise as infertility treatment game-changer and features several benefits and value aspects including a first in Women and Men Phase I clinical trial in Q1 2023.

www.igyxos.com/

LUNAC Therapeutics Ltd

LUNAC Therapeutics is developing the next generation of anti-thrombotics. Our vision is to develop treatments that give patients protection from blood clots - but without the side-effect risks of severe bleeding. By targeting part of the thrombotic system that is involved in pathological thrombosis, but not normal clotting, we aim to offer patients and healthcare practitioners safer and effective treatments. LUNAC is at the stage of taking its' small molecules to lead-optimisation and is ready to partner with investors for the next stage of our development.

www.lunactherapeutics.com/

Metafora Biosystems

METAFORA: AI-powered single-cell & metabolic profiling for discovery, development & diagnostics.

METAFORA is pioneering a digital, clinical grade Flow Cytometry platform, and unique capabilities to decipher cell metabolism. Our assets are breakthrough foundations for the development of innovative solutions in diagnostics and cell therapies.

METAFORA's platform can address three markets:
1. The global flow cytometry market with its AI-powered digital platform.
2. IVD testing using clinical flow cytometry-based assays, including proprietary assays around cell metabolism.
3. IO Cell therapies’ metabolic fitness optimization.

1. METAflow RUO is a commercial-stage SaaS software available for the Research activities of academia, pharma and CROs.

2. METAflow clinical is a development-stage first in kind clinical grade flow cytometry 360º platform. It will combine validated reagent kits for sample preparation, automated data analysis & comprehensive data visualizations, ensuring high quality and fast clinical results. First indications target a neuro-metabolic disorder and hemato-onco diseases, with an expanding menu of potential tests in cancer, immunology or inflammatory disorders.
The first CE-IVD test, METAglut1, dedicated to the early diagnosis of the glucose transporter 1 deficiency syndrome in pediatric patients, is already commercialized.

3. META-cart is a clinical stage program using our Flow Cytometry and cell metabolism platform as an enabling technology for the optimization of CAR-T cell therapy. This solution is developed in partnership with biotechs and academia (NIH / NCI).

Created in 2011 and based in Paris, METAFORA has assembled a multidisciplinary team, with a blend of entrepreneurs, biologists and data scientists. So far, the company raised €17m.

www.metafora-biosystems.com/

NLC - Elithia Biotech Fund

NLC is Europe's largest healthtech venture builder (more information on the NLC website: www.nlc.health). We incorporate new start-ups around breakthrough life-science innovations originating from European academic hospitals (e.g. Charité), universities (e.g. Oxford), research institutes (e.g. INSERM) and corporates (e.g. Philips, DSM). Since our founding in 2015, we have now built over 90 start-ups.

Currently, we are actively fundraising for our newest (fourth) fund, the Elithia Biotech Fund.

Named after the Greek goddess of birth, this Fund will invest in 22 promising new biotech start-ups in the neurology and immunology space. Some more highlights include:
- The fund will invest in 22 projects over 4 years
- Exit horizon 4-10 years
- Fund size: €12.5 million
- Projected IRR: 23%
- Projected Money Multiple: 3.2x
​
We are interested to meet up during the conference with potential partners who share our mission of bringing science to life.

www.nlc.health

Pan Cancer T B.V.

Pan Cancer T is a spin-off startup from Erasmus MC (Rotterdam, the Netherlands). We develop best-in-class T cell receptor (TCR) T cell therapies, focusing on a series of untapped tumor targets. Our mission is to become the leader in tailored and breakthrough life-saving therapeutics for large cohorts of patients with solid cancer.

Pan Cancer T’s strategy tackles two major obstacles preventing TCR-T therapies to expand to the main solid cancer types. We leverage our clinically de-risked TCR-T platform by identifying high-value untapped cancer targets and expanding into new indications with high patient numbers that are not targeted by current TCR-T’s and deepening the responses for patients by helping the TCR-T’s to overcome the highly suppressive and inhibitory solid cancer Tumor Microenvironment.

Our lead program, PCT-1, has demonstrated a compelling preclinical proof of concept. The PCT-1 program focuses on triple-negative breast cancer and melanoma. Other potential oncology indications include bladder, ovarian, lung, esophagus, colon, prostate, and glioma.

The company is funded by Erasmus MC, Van Herk Ventures, Swanbridge Capital, and Thuja Capital.

www.pancancer-t.com

PDC*line Pharma SA

PDC*line Pharma is a clinical-stage spin-off of the French Blood Bank that develops a new class of potent and off-the-shelf therapeutic cancer vaccines based on a proprietary cell line of Plasmacytoid Dendritic Cells (PDC*line). Based on a robust preclinical package and a first-in-human phase Ib in melanoma, PDC*line Pharma has initiated a clinical development in lung cancer with a new candidate (PDC*lung) and neoantigens (PDC*neo).
​
PDC*line is the only cell line of ready-to-use Dendritic Cells for therapeutic use. It is loaded with synthetic peptides derived from tumor antigens, irradiated, and can be stored frozen for years. After thawing, it is injected to activate in vivo a potent cytotoxic anti-tumor CD8+ T-cell response. The product comes in the form of 3 candidates:

• PDC*mel: our first candidate for melanoma completed a first-in-human phase Ib trial in 2017, demonstrating the safety of the product, the ab-sence of allogeneic rejection and its biological activity. The results of the trial have been pub-lished in the Oncoimmunology journal in 2020.
• PDC*lung: our leading candidate for non-small-cell lung cancer (NSCLC) targets widely ex-pressed shared antigens (including cancer/testis antigens). A phase Ib/II trial on 64 patients evalu-ating its safety, biological activity, and preliminary clinical activity, with and without anti-PD1, is cur-rently on-going.
• PDC*neo: is currently being developed at the preclinical stage.

PDC*line Pharma comprises a team of 29 persons based in Belgium and France. The company has raised nearly €52M. The last rounds have been led by the Asian leading VC Korean Investment Partners.
In March 2019, PDC*line Pharma granted an exclusive license in South Korea and exclusive option in other Asian countries to LG Chem Life Sciences Company, for the development and commercializa-tion of PDC*lung cancer vaccine for lung cancer. The total deal value is €108M (123M$) plus royalties on net sales in Asia.
​
www.pdc-line-pharma.com

Prokarium Ltd.

Prokarium is harnessing evolution to cure difficult to treat cancers by applying cutting edge science at the intersection of immunology and synthetic biology. The company’s mission is to design the perfect bacteria to be the next cancer immunotherapy platform.

www.prokarium.com

SciRhom GmbH

SciRhom GmbH is developing First-in-class antibodies against iRhom2 - a key regulator of an inflammatory master switch (TACE) - with a unique mode of action for treatment of Autoimmune Diseases.

The selected clinical candidate is currently being further profiled in order to allow for a CTA / IND submission in 3Q 2023, followed by a subsequent start of clinical studies in late 2023 / ealry 2024.

scirhom.com/

SOM Biotech SA

SOM Biotech SA is a clinical-stage biopharmaceutical company leveraging the power of artificial intelligence ("AI") to develop known drugs for use in orphan diseases. We use our clinically validated and differentiated AI platform 'SOMAIPRO', which identifies potentially better treatment options from known drugs that can be repurposed for new therapeutic indications in areas of high unmet medical needs. SOM Biotech has licensed one drug in Phase 2a for TTR-Amyloidosis and a preclinical one for Glioma and holds a pipeline with three drugs in the clinics (Huntington disease, Phenylketonuria and Tardive diskynesia), along with a big preclinical pipeline.

www.sombiotech.com

Spexis AG
[SIX: SPEX]

Spexis is a clinical-stage, publicly-listed biopharmaceutical company focused on discovering, developing, in-licensing and acquiring first-in-class macrocyclic molecules for rare diseases and cancers. We apply our leading macrocyclic technology platform, which is the result of more than 25 years and $400 million of cumulative research and investment, to discover promising therapeutic candidates that can target difficult-to-drug structures. We have four clinical candidates, with the most advanced (ColiFin, for CF patients, already approved in Europe), entering pivotal P3 studies in North America, Europe and Australia/New Zealand in early 2023. With our pipeline of potentially transformative product candidates – and as our name implies “hope”, from the Latin “spes” – we aim to deliver substantial benefits to patients and meaningful value to society and our stakeholders.

spexisbio.com/

StromaCare

Stromacare is developing a new therapy in oncology based on the immuno-modulation of the tumor stroma using a monoclonal antibody. The tumor stroma is a reaction of the tissue in which the tumor is growing, which inhibits the CD8 T cells and creates a physical barrier preventing access of immune system and therapeutic molecules to the tumor. An overexpressed protein is at the origin of this stromal barrier. Thanks to a specific antibody directed against this protein, the drug candidate is able to reactivate CD8 T lymphocytes and modulate the stroma stiffness, allowing them to reach and act on the tumor and facilitate the action of other therapies. This new approach opens the way to considerable clinical developments, the stroma being common to all solid cancers.

www.stroma.care/

TOLREMO Therapeutics AG

TOLREMO addresses non-genetic resistance mechanisms in cancer using a unique and proprietary drug development platform. Their lead molecule is IND ready and can be combined with blockbuster cancer drugs like KRAS or EGFR inhibitors enabling them to reach their full therapeutic potential and maximizing patient benefit. The company is seeking USD 40M to finance two Phase I/II trials where the lead molecule is tested as monotherapy and in combination with a KRAS inhibitor. The funds will also be used to further advance the company's pipeline of novel resistance modulators.

www.tolremo.com

wmt ag

WMT has discovered novel proprietary small molecules for the treatment of advanced cancers. Our advanced lead cpds target sec61m the ER protein translocon, thereby inducing a metabolic "lockdown" in cancer cells and inhibiting secretion of immunosuppressive proteins.
​
Cancer selectivity is provided through a unique phyiscochemistry of these drugs that are highly enriched in cancer tissue as opposed to normal tissues.

We aim in raising a series A of 20+ M Euros to demonstrate clinical proof of concept in advanced cancers with high baseline proteotoxic stress.

www.wm-therapeutics.com/

Rising stars session

Alithea Bio UG

Alithea Bio is based on the HLA peptidome platform technology combining highly sensitive assays and strong bioinformatics. The company was founded in 2019 and has partnered with several cell and gene therapy companies which Alithea supports in speeding up time to IND by providing target validation, QC, on- and off-target toxicity screening.

Besides, Alithea has a large HLA peptide database (>1 Million ligands) for target discovery and is working on the implementation of precision medicine technologies for peptide-HLA-targeted therapies such as cancer vaccines, TCR T cells and T cell engagers.

www.alithea-bio.com

BioFi AG

BioFi’s proprietary technology CellSim™ provides virtual modeling and simulation solutions for living organisms. From single cell bacteria to developed cancers, starting with simulated biological building blocks, CellSim™ enables the development and growth of virtual cells and tissues. These virtual cells and tissues enable versatile experimentation to investigate biological mechanisms and make predictions. Applications include drug discovery and development and synthetic biology.

CellSim™ can be understood as a virtual cell biology laboratory to guide and complement wet-lab research, enabling rapid virtual experimentation with results interpretable in the biological context.

biofi.ch/

​Dillico

Dillico, an early-stage company funded in May 2022, proposes an optimized solution for companies who want to develop and manufacture mRNA-based therapeutics & leverage mRNA benefits.

Current mRNA Manufacturing processes (for covid vaccines) are suboptimal and do not reach full potential of mRNA technology.

Our Continuous mRNA Manufacturing Solution helps pharmaceutical companies who want to efficiently manufacture mRNA encapsulated therapeutics:
- By directly scaling up process
- With limited personnel and infrastructure
- Offering high-capacity flexibility
- Improving productivity and COGS
- Facilitating regional sustainable capacities
- While keeping robust process performances and high product quality

www.linkedin.com/company/dillico/

​Dimericon Therapeutics AG

DimericonTx was founded in 2021 by a team of experienced biotech executives to fight cancer by targeting protein-protein interactions. The company's SNAPSHOT discovery engine rapidly translates metastable conformations of intrinsically disordered proteins into a new therapeutic modality: Dimericons. These crosslinked helix dimers open up a new target space by merging the best of biologics and small molecules. A growing portfolio of precision oncology projects exploiting novel synthetic lethality relationships is focused on re-activation of extrinsic apoptosis, pan-Ras inhibition and other notorious oncogenic drivers. The lead project (cFLIP inhibition) initially aims at a genetically defined population of AML/MDS patients with particularly poor prognosis. Expansion options include multiple myeloma, lung and ovarian cancer. Combinations with chemotherapy, targeted agents and checkpoint inhibitors promise to be strongly synergistic.

www.dimericon.com/

​JALON Therapeutics

Jalon Therapeutics ambitions to develop new therapies through innovative strategy based on the inactivation of signaling pathways common to most tumors.
​
Jalon Therapeutics is developing cell penetrating peptides that target the protein complexes formed around the survival factor AAC-11. AAC-11 is a cornerstone scaffold protein governing response to cellular stresses triggered by the malignant phenotype and is essential to cancer cell survival.

Jalon Therapeutics drug candidates are composed of AAC-11 sequences that specifically interact with many of its protein partners. They act as decoys to prevent AAC-11 functional interactions. This results in the disruption of AAC-11 complexes and subsequent inhibition of its pro-tumoral functions, specifically inducing cancer cells death. In addition, the lead drug candidate JRT39, upon binding to AAC-11 partners present at the membrane of tumor cells, triggers their destruction through membranolysis.
​
By disrupting protein-protein interactions vital to cancer cells while specifically inducing tumor membranolysis, JRT39 lead drug candidate represents a unique approach for the treatment of cancers.

The approach, fully patented, originates from the pioneering research of Dr Jean-Luc Poyet from Inserm-St Louis hospital (Paris, France). Dr Poyet is expert in cell-penetrating peptides and the development of protein-protein interactions modulators. The approach is backed by Professors Martine Bagot and Hervé Dombret from Saint-Louis Hospital (Paris), medical key opinion leaders in onco dermatology and hematology.

Jalon Therapeutics started in 2021 and has already achieved significant milestones in JRT39 development: process optimization, pre-GMP batch manufacturing, preclinical efficacy, pharmacokinetics, and pre-toxicology studies (murine models, NHP and dogs). Based on this, Jalon Therapeutics plans to initiate JRT39 clinical Phase I/II trial in oncology in early 2024.
​
Jalon Therapeutics raised Seed funding in 2022, leveraged by non-dilutive fundings. Its growth ambition is to raise a Series A to finance up to its clinical proof of concept.

www.jalontx.com

MESOX LTD

'Unleash the Power of Therapeutics'

MESOX is solving the delivery challenges of therapeutics using advanced mesoporous carriers.

https://mesox.co.uk/​

Mosanna Therapeutics AG

Mosanna is a Swiss Biotech company based in Basel with a commitment to improving patient outcomes and quality of life in high unmet need diseases, applying a precision medicine approach. We carefully select innovative medicines for further development using the best contract research organisations in the specific specialised field. Our first goal is to bring an effective and well tolerated medicinal nasal spray to Metabolic Obstructive Sleep Apnea patients.

mosanna.com

Onena Medicines

Onena Medicines is a biopharmaceutical company with a pipeline of first-in-class antibody medicines to treat cancers and selected rare diseases. Onena’s drugs neutralize a new class of secreted ancient growth factors, conserved across species, called Dual SMAD Inhibiting Proteins (DSIPs), that program cancer cells to grow by suppressing environmental cues that instruct cells to commit suicide. Blocking DSIPs, as demonstrated in-vivo by Onena, simultaneously reactivates physiological TGF-β and BMP signaling and elicits cellular reprogramming, resulting in cancer cells that accept environmental cell death signals from BMPs and Activins. Onena has developed a proprietary AI-centric antibody drug discovery platform that rapidly generates anti-DSIP neutralizing antibodies, even when no crystal structure of the antigen is available. OMED-101, Onena’s anti-LEFTY1/2 lead candidate antibody, has demonstrated broad efficacy against breast, colorectal and brain cancers without observable toxicities in preclinical models. Through its unique platform, Onena Medicines has discovered several DSIPs and aims to advance multiple neutralizing DSIP antibody drugs into clinical development in the next three years.

​www.onenameds.com/

Pilatus Biosciences SA

Pilatus Biosciences aims to unlock the immunosuppressive tumor microenviroment for cancer treatment by rewiring immunometabolic circuits in immune cells. The company was launched in December 2021 as a cancer immunometabolism-focused spin-off from UNIL (Université de Lausanne) and now developing potential first-in-class antibody-based metabolic targeting in Lausanne, Switzerland.

​www.biopole.ch/company/pilatus-biosciences-sa/

​Procavea Biotech

Procavea Biotech is a soon-to-be-incorporated ETH Spin-off company that will provide molecular delivery systems for next-generation therapeutics. The target customers are pharmaceutical companies, especially those developing oligonucleotide therapeutics. Procavea's proprietary platform technology is the first of its kind - computationally-designed nonviral protein cages, specifically designed to delivery olgonucleotides into cells. The lack of delivery technologies is widely recognised as limiting the full commercial potential of RNA/DNA therapeutics. Procavea has the means to take this problem head on, providing much needed solutions to pharmaceutical companies and ultimately break down the barriers to get oligonucleotide drugs to patients in need.

www.procavea.com/

Risklick AG

Risklick developed the first of its kind, data-driven solution to predict and mitigate risks in clinical trials before start using AI. We empower investors and consultants to assess the risks associated to clinical development using empirical data. The analysis includes the probability of success, the clinical competitive landscape, and the safety profile, thus optimizing decision-making processes prior to investment. Risklick currently provides customer-centered solutions to diverse investment organizations.

www.risklick.ch/

​Seekyo Therapeutics

At Seekyo, we have developed the next generation of targeted therapy for solid cancer.

Based on our validated and patented SKY™️ platform, Tumor Activated Therapeutics is highly selective in targeting the Tumor Micro-Environment, is potent with efficacy beyond current standards of care and is versatile in various solid cancer indications (Pancreas, TNBC, lung and colorectal)

It builds on the success of the existing treatments like small molecules and ADCs and goes beyond.

www.seekyo-therapeutics.com/

StemInov

StemInov is a clinical stage spin-off from CHRU of Nancy and University of Lorraine Region (UL) that develops an off-the-shelf and allogenic cell therapy treatment in the field of inflammatory pathologies with a focus on critical care. More than a new product, our proprietary Stem cells from the Wharton jelly of umbilical cord (WJ-MSC), called WhartSep, is a new concept of immunomodulation and adaptive medicine firstly indicated and patented for the treatment of septic shock and Acute Respiratory Syndrome Disease (ARDS). Based on a robust preclinical package and largely admitted safety of the treatment, StemInov is preparing a phase I/II efficacy trial in community acquired pneumonia leading to a septic shock or ARDS.

The scale of current manufacturing process available on the market for WJ-MSC allows to perform early-stage clinical trial but cannot be used for human clinical trial with hundreds of patients.

To face this challenge of WJ-MSC supply and master the process and quality of our drug candidate, we have decided to generate internal know-how on the 3D production of these cells and to set up the first European WJ-MSC 3D production unit.

www.linkedin.com/company/steminov/

Virtual Presenters:

20-MINUTE PRESENTERS

ABVC BioPharma, Inc.

ABVC BioPharma is a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and opthamology. The company has an active pipeline of six drugs and one medical device (ABV-1701/Vitargus®) under development. For its drug products, it is focused on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process at world-famous research institutions (such as Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center). For Vitargus®, the company intends to conduct the clinical trials through Phase III at various locations throughout the globe.
​
abvcpharma.com/

eTheRNA

eTheRNA has developed a proprietary and integrated set of platform technologies that are overcoming the challenges facing the development of next generation mRNA therapeutics. Our platforms include mRNA construct design and optimization, proprietary lipid nanoparticles (LNP) and formulations, and in-house process engineering capabilities for mRNA drug substance manufacturing.

www.etherna.be

kbio

Creating the new generation of biologics using its plant-based platform that has demonstrated an ability to create potentially better antibody drug candidates at a fraction of the time and cost of current mammalian cell-based antibody platforms. The Company is focused on developing novel product candidates in two core areas: 1) Antibody therapies for areas of high unmet need 2) Pandemic preparedness and response using its plant-based production system to rapidly create antibodies and vaccines.

kbio.com

10-MINUTE PRESENTERS

​Alertgy, Inc.

Alertgy is a developer of a wearable medical device wristband known as DeepGluco®, which is a truly Non-Invasive Continuous blood Glucose Monitor (NICGM) and alert system to be used by the 422 million diabetics worldwide as well as non-diabetics for real-time blood glucose measurement.

www.alertgy.com/

​Heidelberg Epignostix GmbH iG

Profile to be added shortly..

5-minute presenters

genesis theranostix

76,000 maternal and 500,000 baby lives can be saved and 7-10 million severe pregnancy complications can be prevented every year with our early pregnancy diagnostics test followed by patient-tailored therapies. The founders – ex-colleagues at NIH – based this unique and best-in-class technology on proprietary patent and know-how utilizing the tools of systems biology and precision medicine.
​
www.genesistheranostix.com